COMP <GO>
PRQR vs ADCT // FORWARD P/E MULTIPLE
ProQR Therapeutics N.V. (NASDAQ) VS. ADC Therapeutics SA (NYSE) • 15-METRIC TALLY: PRQR 0
— ADCT 2
■ METRIC PARITY
LAST: $1.37 (+3.79%) • MKT CAP: $186.3M
forward-pe
—
LAST: $1.55 (+0.65%) • MKT CAP: $196.6M
forward-pe
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PRQR VS. ADCT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PRQR | ADCT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 92.90% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | -35.00% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 14.90% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 5/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 36.6 | 54.3 | -17.70 | ADCT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $186.3M | $196.6M | -$10.3M | ADCT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PRQR REV | ADCT REV | PRQR GROSS % | ADCT GROSS % | PRQR FCF | ADCT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $81.4M | — | 92.9% | — | -$141.4M |
| FY 2024 | — | $70.8M | — | 91.6% | — | -$124.7M |
| FY 2023 | — | $69.1M | — | — | — | -$118.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PRQR // BETA —
ADCT // BETA —